Screening for familial and hereditary prostate cancer

International Journal of Cancer

Volumn 138, Issue 11, 2016, Pages 2579-2591

  Lynch, Henry T ^a   Kosoko Lasaki, Omofolasade ^a   Leslie, Stephen W ^b   Rendell, Marc ^b   Shaw, Trudy ^a   Snyder, Carrie ^a   D'Amico, Anthony V ^c   Buxbaum, Sarah ^d   Isaacs, William B ^e   Loeb, Stacy ^f   Moul, Judd W ^g   Powell, Isaac ^h  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CREIGHTON UNIVERSITY MEDICAL CENTER   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d JACKSON STATE UNIVERSITY   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f NEW YORK UNIVERSITY   (United States)

^g DUKE UNIVERSITY MEDICAL CENTER   (United States)

^h WAYNE STATE UNIVERSITY   (United States)

Author keywords

BRCA2; genome wide association studies; HOXB13; prostate cancer; prostate specific antigen

Indexed keywords

BRCA2 PROTEIN; BRCA2 PROTEIN, HUMAN; HOMEODOMAIN PROTEIN; HOXB13 PROTEIN, HUMAN; TUMOR MARKER;

ADVANCED CANCER; CANCER RISK; CANCER SCREENING; CANCER SUSCEPTIBILITY; ETHNICITY; FAMILIAL CANCER; FAMILY HISTORY; FIRST DEGREE RELATIVE; GENE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC RISK; GLEASON SCORE; HOXB13 GENE; HUMAN; HUMAN PROSTATE CANCER 1 GENE; HUMAN PROSTATE CANCER X GENE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR SUPPRESSOR GENE; EARLY CANCER DIAGNOSIS; GENETICS; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; GERMLINE MUTATION; MALE; PATHOLOGY; PROSTATE TUMOR;

BIOMARKERS, TUMOR; BRCA2 PROTEIN; EARLY DETECTION OF CANCER; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; GERM-LINE MUTATION; HOMEODOMAIN PROTEINS; HUMANS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS;

EID: 84962299831     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29949     Document Type: Review

References (146)

1. Franks LM., Latent carcinoma of the prostate. J Pathol Bacteriol 1954; 68: 603-6.
2. Sakr WA, Haas GP, Cassin BF, et al., The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol 1993; 150 (2 Pt 1): 379-85.
3. Zlotta AR, Egawa S, Pushkar D, et al., Prevalence of prostate cancer on autopsy: cross-sectional study on unscreened Caucasian and Asian men. J Natl Cancer Inst 2013; 105: 1050-8.
4. Xu J, Zheng SL, Isaacs SD, et al., Inherited genetic variant predisposes to aggressive but not indolent prostate cancer. Proc Natl Acad Sci USA 2010; 107: 2136-40.
5. Daniel W, Lin DW, Porter M, Montgomery B., Treatment and survival outcomes in young men diagnosed with prostate cancer: a population based cohort study. Cancer 2009; 115: 2863-71.
6. Kohler BA, Ward E, McCarthy BJ, et al., Annual report to the nation on the status of cancer, 1975-2007, featuring tumors of the brain and other nervous system. J Natl Cancer Inst 2011; 103: 714-36.
7. Scosyrev E, Wu G, Mohile S, Messing EM., Prostate-specific antigen screening for prostate cancer and risk of overt metastatic disease at presentation: Analysis of trends over time. Cancer 2012; 118: 5768-76.
8. Ganz PA, Barry JM, Burke W, et al., National Institutes of Health State-of-the-Science Conference: role of active surveillance in the management of men with localized prostate cancer. Ann Intern Med 2012; 156: 591-5.
9. Moyer VA, on behalf of the U.S.Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012; 157: 120-34.
10. Catalona WJ, D'Amico AV, Fitzgibbons WF, et al., What the U.S. Preventive Task Force missed in its PCa screening recommendation. Ann Intern Med 2012; 157: 137-8.
11. Lichtenstein P, Holm NV, Verkasalo PK, et al., Environmental and heritable factors in the causation of cancer: analysis of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 2000; 343: 78-85.
12. Hjelmborg JB, Scheike T, Holst K, et al., The heritability of prostate cancer in the Nordic Twin Study of Cancer. Cancer Epidemiol Biomarkers Prev 2014; 23: 2303-10.
13. Verhage BA, Aben KK, Witjes JA, et al., Site-specific familial aggregation of prostate cancer. Int J Cancer 2004; 109: 611-7.
14. Gianferrari L, Arrigoni G, Cresseri A, et al., Recherches clinicostatistiques et genetiques sur les neoplasies de la prostate. Acta Genet Med Gemellol (Roma) 1956; 5: 224-33.
15. Johns LE, Houlston RS., A systematic review and meta-analysis of familial prostate cancer risk. BJU Int 2003; 91: 789-94.
16. Zeegers MPA, Jellema A, Ostrer H., Empiric risk of prostate carcinoma for relatives of patients with prostate carcinoma: a meta-analysis. Cancer 2003; 97: 1894-903.
17. Negri E, Pelucchi C, Talamini R, et al., Family history of cancer and the risk of prostate cancer and benign prostatic hyperplasia. Int J Cancer 2005; 114: 648-52.
18. Bratt O, Garmo H, Adolfsson J, et al., Effects of prostate-specific antigen testing on familial prostate cancer risk estimates. J Natl Cancer Inst 2010; 102: 1336-43.
19. Jansson KF, Akre O, Garmo H, et al., Concordance of tumor differentiation among brothers with prostate cancer. Eur Urol 2012; 62: 656-61.
20. Hemminki K., Familial risk and familial survival in prostate cancer. World J Urol 2012; 30: 143-8.
21. Albright F, Stephenson RA, Agarwal N, et al., Prostate cancer risk prediction based on complete prostate cancer family history. Prostate 2015; 75: 390-8.
22. Carter BS, Beaty TH, Steinberg GD, et al., Mendelian inheritance of familial prostate cancer. Proc Natl Acad Sci USA 1992; 89: 3367-71.
23. Schaid DJ, McDonnell SK, Blute ML, Thibodeau SN., Evidence for autosomal dominant inheritance of prostate cancer. Am J Hum Genet 1998; 62: 1425-38.
24. Gronberg H, Damber L, Damber JE, Iselius L., Segregation analysis of prostate cancer in Sweden: support for dominant inheritance. Am J Epidemiol 1997; 146: 552-7.
25. Carter BS, Bova GS, Beaty TH, et al., Hereditary prostate cancer: epidemiologic and clinical features. J Urol 1993; 150: 797-802.
26. Cooney KA, McCarthy JD, Lange E, et al., Prostate cancer susceptibility locus on chromosome 1q: a confirmatory study. J Natl Cancer Inst 1997; 89: 955-9.
27. Xu J, the International Consortium for Prostate Cancer Genetics. Combined analysis of hereditary prostate cancer linkage to 1q24-25: results from 772 hereditary prostate cancer families from the International Consortium for Prostate Cancer Genetics. Am J Hum Genet 2000; 66: 945-57.
28. Neuhausen SL, Farnham JM, Kort E, et al., Prostate cancer susceptibility locus HPC1 in Utah high-risk pedigrees. Hum Mol Genet 1999; 8: 2437-42.
29. Schleutker J, Matikainen M, Smith J, et al., A genetic epidemiological study of hereditary prostate cancer (HPC) in Finland: frequent HPCX linkage in families with late-onset disease. Clin Cancer Res 2000; 6: 4810-5.
30. Bochum S, Paiss T, Vogel W, et al., Confirmation of the prostate cancer susceptibility locus HPCX in a set of 104 German prostate cancer families. Prostate 2002; 52: 12-9.
31. Farnham JM, Camp NJ, Swensen J, et al., Confirmation of the HPCX prostate cancer predisposition locus in large Utah prostate cancer pedigrees. Hum Genet 2005; 116: 179-85.
32. Berthon P, Valeri A, Cohen-Akenine A, et al., Predisposing gene for early-onset prostate cancer, localized on chromosome 1q42.2-43. Am J Hum Genet 1998; 62: 1416-24.
33. Brown WM, Lange EM, Chen H, et al., Hereditary prostate cancer in African American families: linkage analysis using markers that map to five candidate susceptibility loci. Br J Cancer 2004; 90: 510-4.
34. Baffoe-Bonnie AB, Kittles RA, Gillanders E, et al., Genome-wide linkage of 77 families from the African American Hereditary Prostate Cancer Study (AAHPC). Prostate 2007; 67: 22-31.
35. Ewing CM, Ray AM, Lange EM, et al., Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med 2012; 366: 141-9.
36. Kote-Jarai Z, Leongamornlert D, Saunders E, et al., BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients. Br J Cancer 2011; 105: 1230-4.
37. Gudmundsson J, Sulem P, Rafnar T, et al., Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat Genet 2008; 40: 281-3.
38. Slager SL, Zarfas KE, Brown WM, et al., Genome-wide linkage scan for prostate cancer aggressiveness loci using families from the University of Michigan Prostate Cancer Genetics Project. Prostate 2006; 66: 173-9.
39. Liu X, Cheng I, Plummer SJ, et al., Fine-mapping of prostate cancer aggressiveness loci on chromosome 7q22-35. Prostate 2011; 71: 682-9.
40. Witte JS, Goddard KA, Conti DV, et al., Genomewide scan for prostate cancer-aggressiveness loci. Am J Hum Genet 2000; 67: 92-9.
41. Neville PJ, Conti DV, Paris PL, et al., Prostate cancer aggressiveness locus on chromosome 7q32-q33 identified by linkage and allelic imbalance studies. Neoplasia 2002; 4: 424-31.
42. Cheng I, Plummer SJ, Neslund-Dudas C, et al., Prostate cancer susceptibility variants confer increased risk of disease progression. Cancer Epidemiol Biomarkers Prev 2010; 19: 2124-32.
43. Cheng I, Plummer SJ, Jorgenson E, et al., 8q24 and prostate cancer: association with advanced disease and meta-analysis. Eur J Hum Genet 2008; 16: 496-505.
44. Nurminen R, Wahlfors T, Tammela TL, Schleutker J., Identification of an aggressive prostate cancer predisposing variant at 11q13. Int J Cancer 2011; 129: 599-606.
45. FitzGerald LM, Kwon EM, Conomos MP, et al., Genome-wide association study identifies a genetic variant associated with risk for more aggressive prostate cancer. Cancer Epidemiol Biomarkers Prev 2011; 20: 1196-203.
46. Duggan D, Zheng SL, Knowlton M, et al., Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. J Natl Cancer Inst 2007; 99: 1836-44.
47. Lindstrom S, Schumacher F, Siddiq A, et al., Characterizing associations and SNP-environment interactions for GWAS-identified prostate cancer risk markers-results from BPC3. PLoS One 2011; 6: e17142.
48. Mitra A, Fisher C, Foster CS, IMPACT and EMBRACE Collaborators, et al. Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype. Br J Cancer 2008; 98: 502-7.
49. Gallagher DJ, Gaudet MM, Pal P, et al., Germline BRCA mutations denote a clinicopathologic subset of prostate cancer. Clin Cancer Res 2010; 16: 2115-21.
50. Edwards SM, Evans DG, Hope Q, et al., Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis. Br J Cancer 2010; 103: 918-24.
51. Williams H, Powell IJ., Epidemiology, pathology, and genetics of prostate cancer among African Americans compared with other ethnicities. In:, Verma M, ed. Cancer epidemiology. Totowa, NJ: Humana Press, 2009. 439-53.
52. Powell IJ, Bock CH, Ruterbusch JJ, Sakr W., Evidence supports a faster growth rate and/or earlier transformation to clinically significant PCa in black than in white American men, and influences racial progression and mortality disparity. J Urol 2010; 183: 1792-6.
53. Robbins AS, Whittemore AS, Thom DH., Differences in socioeconomic status and survival among White and Black men with prostate cancer. Am J Epidemiol 2000; 151: 409-16.
54. Freedland SJ, Isaacs WB., Explaining racial differences in prostate cancer in the United States: Sociology or biology? Prostate 2005; 62: 243-52.
55. Evans S, Metcalfe C, Ibrahim F, et al., Investigating Black-White differences in prostate cancer prognosis: A systematic review and meta-analysis. Int J Cancer 2008; 123: 430-5.
56. Lynch HT, Larsen AL, Magnuson CW, Krush AJ., Prostate carcinoma and multiple primary malignancies: study of a family and 109 consecutive prostate cancer patients. Cancer 1966; 19: 1891-7.
57. Bauer CM, Ray AM, Halstead-Nussloch BA, et al., Hereditary prostate cancer as a feature of Lynch syndrome. Fam Cancer 2011; 10: 37-42.
58. Raymond VM, Mukherjee B, Wang F, et al., Elevated risk of prostate cancer among men with Lynch syndrome. J Clin Oncol 2013; 31: 1713-8.
59. Agalliu I, Kwon EM, Zadory D, et al., Germline mutations in the BRCA2 gene and susceptibility to hereditary prostate cancer. Clin Cancer Res 2007; 13: 839-50.
60. van Asperen CJ, Brohet RM, Meijers-Heijboer EJ, et al., Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. J Med Genet 2005; 42: 711-9.
61. Thorne H, Willems AJ, Niedermayr E, et al, Kathleen Cunningham Consortium for Research into Familial Breast Cancer Consortium (kConFab). Decreased prostate cancer-specific survival of men with BRCA2 mutations from multiple breast cancer families. Cancer Prev Res 2011; 4: 1002-10.
62. Moran A, O'Hara C, Khan S, et al., Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations. Fam Cancer 2012; 11: 235-42.
63. Kammerer S, Roth RB, Reneland R, et al., Large-scale association study identifies ICAM region as breast and prostate cancer susceptibility locus. Cancer Res 2004; 64: 8906-10.
64. Brandt A, Sundquist J, Hemminki K., Risk for incident and fatal prostate cancer in men with a family history of any incident and fatal cancer. Ann Oncol 2012; 23: 251-6.
65. Win AK, Lindor NM, Young JP, et al., Risks of primary extracolonic cancers following colorectal cancer in Lynch syndrome. J Natl Cancer Inst 2012; 104: 1363-72.
66. FitzGerald LM, McDonnell SK, Carlson EE, et al., Genome-wide linkage analyses of hereditary prostate cancer families with colon cancer provide further evidence for a susceptibility locus on 15q11-q14. Eur J Hum Genet 2010; 18: 1141-7.
67. Cheng I, Kocarnik JM, Dumitrescu L, et al., Pleiotropic effects of genetic risk variants for other cancers on colorectal cancer risk: PAGE, GECCO and CCFR consortia. Gut 2014; 63: 800-7.
68. Rafnar T, Sulem P, Stacey SN, et al., Sequence variants at the TERT-CLPTM1L locus associate with many cancer types. Nat Genet 2009; 41: 221-7.
69. Johanneson B, Deutsch K, McIntosh L, et al., Suggestive genetic linkage to chromosome 11p11.2-q12.2 in hereditary prostate cancer families with primary kidney cancer. Prostate 2007; 67: 732-42.
70. Beebe-Dimmer JL, Levin AM, Ray AM, et al., Chromosome 8q24 markers: risk of early-onset and familial prostate cancer. Int J Cancer 2008; 122: 2876-9.
71. Sotelo J, Esposito D, Duhagon MA, et al., Long-range enhancers on 8q24 regulate c-Myc. Proc Natl Acad Sci U S A 2010; 107: 3001-5.
72. Meyer KB, Maia A-T, O'Reilly M, et al., A functional variant at a prostate cancer predisposition locus at 8q24 is associated with PVT1 expression. PLoS Genet 2011; 7: e1002165.
73. Wokolorczyk D, Gliniewicz B, Sikorski A, et al., A range of cancers is associated with the rs6983267 marker on chromosome 8. Cancer Res 2008; 68: 9982-6.
74. Ghoussaini M, Song H, Koessler T, et al., Multiple loci with different cancer specificities within the 8q24 gene desert. J Natl Cancer Inst 2008; 100: 962-6.
75. Brisbin AG, Asmann YW, Song H, et al., Meta-analysis of 8q24 for seven cancers reveals a locus between NOV and ENPP2 associated with cancer development. BMC Med Genet 2011; 12: 156.
76. Stadler ZK, Schrader KA, Vijai J, Robson ME, Offit K., Cancer genomics and inherited risk. J Clin Oncol 2014; 32: 687-98.
77. Moyer VA., Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med 2013;, 160,: 271-81.
78. Dewey FE, Grove ME, Pan C, et al., Clinical interpretation and implications of whole-genome sequencing. JAMA 2014; 311: 1035-45.
79. Shui IM, Lindström S, Kibel AS, et al., Prostate cancer (PCa) risk variants and risk of fatal PCa in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. Eur Urol 2014; 65: 1069-75.
80. Loeb S, Peskoe SB, Joshu CE, et al., Do environmental factors modify the genetic risk of prostate cancer? Cancer Epidemiol Biomarkers Prev 2015; 24: 213-20.
81. Gudmundsson J, Besenbacher S, Sulem P, et al., Genetic correction of PSA values using sequence variants associated with PSA levels. Sci Transl Med 2010; 2: 62ra92.
82. Loeb S, Carter HB, Walsh PC, et al., Single nucleotide polymorphisms and the likelihood of prostate cancer at a given prostate specific antigen level. J Urol 2009; 182: 101-4.
83. Helfand BT, Loeb S, Hu Q, et al., Personalized prostate specific antigen testing using genetic variants may reduce unnecessary prostate biopsies. J Urol 2013; 189: 1697-701.
84. Helfand BT, Loeb S, Kan D, Catalona WJ., Number of prostate cancer risk alleles may identify possibly 'insignificant' disease. BJU Int 2010; 106: 1602-6.
85. Zheng SL, Sun J, Wiklund F, et al., Cumulative association of five genetic variants with prostate cancer. N Engl J Med 2008; 358: 910-9.
86. Salinas CA, Koopmeiners JS, Kwon EM, et al., Clinical utility of five genetic variants for predicting prostate cancer risk and mortality. Prostate 2009; 69: 363-72.
87. Sun J, Chang BL, Isaacs SD, et al., Cumulative effect of five genetic variants on prostate cancer risk in multiple study populations. Prostate 2008; 68: 1257-62.
88. Helfand BT, Fought AJ, Loeb S, et al., Genetic prostate cancer risk assessment: common variants in 9 genomic regions are associated with cumulative risk. J Urol 2010; 184: 501-5.
89. Zheng SL, Sun J, Wiklund F, et al., Genetic variants and family history predict prostate cancer similar to prostate-specific antigen. Clin Cancer Res 2009; 15: 1105-11.
90. Xu J, Sun J, Kader AK, et al., Estimation of absolute risk for prostate cancer using genetic markers and family history. Prostate 2009; 69: 1565-72.
91. Sun J, Lange EM, Isaacs SD, et al., Chromosome 8q24 risk variants in hereditary and non-hereditary prostate cancer patients. Prostate 2008; 68: 489-97.
92. Nam RK, Zhang WW, Trachtenberg J, et al., Utility of incorporating genetic variants for the early detection of prostate cancer. Clin Cancer Res 2009; 15: 1787-93.
93. Dudbridge F., Power and predictive accuracy of polygenic risk scores. PLoS Genet 2013; 9: e1003348
94. Machiela MJ, Chen CY, Chen C, et al., Evaluation of polygenic risk scores for predicting breast and prostate cancer risk. Genet Epidemiol. 2011 Sep; 35: 506-14.
95. Christensen GB, Baffoe-Bonnie A, George A, et al., Genome-wide linkage analysis of 1,233 prostate cancer pedigrees from the International Consortium for Prostate Cancer Genetics using novel sumLINK and sumLOD analyses. Prostate 2010; 70: 735-44.
96. Eeles RA, Al Olama AA, Benlloch S, et al., Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet 2013; 45: 385-91.
97. Xu J, Zheng SL, Chang B, et al., Linkage of prostate cancer susceptibility loci to chromosome 1. Hum Genet 2001; 108: 335-45.
98. Nam RK, Zhang WW, Loblaw DA, et al., A genome-wide association screen identifies regions on chromosomes 1q25 and 7p21 as risk loci for sporadic prostate cancer. Prostate Cancer Prostatic Dis 2008; 11: 241-6.
99. Sun T, Lee GS, Oh WK, et al., Single-nucleotide polymorphisms in p53 pathway and aggressiveness of prostate cancer in a Caucasian population. Clin Cancer Res 2010; 16: 5244-51.
100. Matsui H, Suzuki K, Ohtake N, et al., Genomewide linkage analysis of familial prostate cancer in the Japanese population. J Hum Genet 2004; 49: 9-15.
101. Gong M, Dong W, Shi Z, et al., Genetic polymorphisms of GSTM1, GSTT1, and GSTP1 with prostate cancer risk: a meta-analysis of 57 studies. PLoS ONE 2012; 7: e50587
102. Gudmundsson J, Sulem P, Gudbjartsson DF, et al., Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility. Nat Genet 2009; 41: 1122-6.
103. Kote-Jarai Z, Olama AA, Giles GG, et al., Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. Nat Genet 2011; 43: 785-91.
104. Akamatsu S, Takata R, Haiman CA, et al., Common variants at 11q12, 10q26 and 3p11.2 are associated with prostate cancer susceptibility in Japanese. Nat Genet 2012; 44: 426-9.
105. Ledet EM, Sartor O, Rayford W, et al., Suggestive evidence of linkage identified at chromosomes 12q24 and 2p16 in African American prostate cancer families from Louisiana. Prostate 2012; 72: 938-47.
106. Long QZ, Du YF, Ding XY, et al., Replication and fine mapping for association of the C2orf43, FOXP4, GPRC6A and RFX6 genes with prostate cancer in the Chinese population. PLoS ONE 2012; 7: e37866
107. Takata R, Akamatsu S, Kubo M, et al., Genome-wide association study identifies five new susceptibility loci for prostate cancer in the Japanese population. Nat Genet 2010; 42: 751-4.
108. Qi J, Tian L, Chen Z, et al., Genetic variants in 2q31 and 5p15 are associated with aggressive benign prostatic hyperplasia in a Chinese population. Prostate 2013; 73: 1182-90.
109. Gillanders EM, Xu J, Chang B-L, et al., Combined genome-wide scan for prostate cancer susceptibility genes. J Natl Cancer Inst 2004; 96: 1240-7.
110. Cropp CD, Simpson CL, Wahlfors T, et al., Genome-wide linkage scan for prostate cancer susceptibility in Finland: evidence for a novel locus on 2q37.3 and confirmation of signal on 17q21-22. Int J Cancer 2011; 129: 2400-7.
111. Larson GP, Ding Y, Cheng LSC, et al., Genetic linkage of prostate cancer risk to the chromosome 3 region bearing FHIT. Cancer Res 2005; 65: 805-14.
112. Schleutker J, Baffoe-Bonnie AB, Gillanders E, et al., Genome-wide scan for linkage in Finnish hereditary prostate cancer (HPC) families identifies novel susceptibility loci at 11q14 and 3p25-26. Prostate 2003; 57: 280-9.
113. Rökman A, Baffoe-Bonnie AB, Gillanders E, et al., Hereditary prostate cancer in Finland: fine-mapping validates 3p26 as a major predisposition locus. Hum Genet 2005; 116: 43-50.
114. Eeles RA, Kote-Jarai Z, Al Olama AA, et al., Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat Genet 2009; 41: 1116-21.
115. Wiklund F, Gillanders EM, Albertus JA, et al., Genome-wide scan of Swedish families with hereditary prostate cancer: suggestive evidence of linkage at 5q11.2 and 19p13.3. Prostate 2003; 57: 290-7.
116. Bock CH, Schwartz AG, Ruterbusch JJ, et al., Results from a prostate cancer admixture mapping study in African-American men. Hum Genet 2009; 126: 637-42.
117. Huang SP, Bao BY, Hour TC, et al., Genetic variants in CASP3, BMP5, and IRS2 genes may influence survival in prostate cancer patients receiving androgen-deprivation therapy. PLoS ONE 2012; 7: e41219
118. Prokunina-Olsson L, Fu YP, Tang W, et al., Refining the prostate cancer genetic association within the JAZF1 gene on chromosome 7p15.2. Cancer Epidemiol Biomarkers Prev 2010; 19: 1349-55.
119. Chang BL, Spangler E, Gallagher S, et al., Validation of genome-wide prostate cancer associations in men of African descent. Cancer Epidemiol Biomarkers Prev 2011; 20: 23-32.
120. Thomas G, Jacobs KB, Yeager M, et al., Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet 2008; 40: 310-5.
121. Friedrichsen DM, Stanford JL, Isaacs SD, et al., Identification of a prostate cancer susceptibility locus on chromosome 7q11-21 in Jewish families. Proc Natl Acad Sci USA 2004; 101: 1939-44.
122. Wiklund F, Jonsson BA, Goransson I, et al., Linkage analysis of prostate cancer susceptibility: confirmation of linkage at 8p22-23. Hum Genet 2003; 112: 414-8.
123. Maier C, Vesovic Z, Bachmann N, et al., Germline mutations of the MSR1 gene in prostate cancer families from Germany. Hum Mutat 2006; 27: 98-102.
124. Al Olama AA, Kote-Jarai Z, Giles GG, et al., Multiple loci on 8q24 associated with prostate cancer susceptibility. Nat Genet 2009; 41: 1058-60.
125. Benford ML, VanCleave TT, Lavender NA, et al., 8q24 sequence variants in relation to prostate cancer risk among men of African descent: A case-control study. BMC Cancer 2010; 10: 334
126. Amundadottir LT, Sulem P, Gudmundsson J, et al., A common variant associated with prostate cancer in European and African populations. Nat Genet 2006; 38: 652-8.
127. Freedman ML, Haiman CA, Patterson N, et al., Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men. Proc Natl Acad Sci USA 2006; 103: 14068-73.
128. Robbins C, Torres JB, Hooker S, et al., Confirmation study of prostate cancer risk variants at 8q24 in African Americans identifies a novel risk locus. Genome Res 2007; 17: 1717-22.
129. Schumacher FR, Feigelson HS, Cox DG, et al., A common 8q24 variant in prostate and breast cancer from a large nested case-control study. Cancer Res 2007; 67: 2951-56.
130. Bensen JT, Xu Z, McKeigue PM, et al., Admixture mapping of prostate cancer in African Americans participating in the North Carolina-Louisiana Prostate Cancer Project (PCaP). Prostate 2014; 74: 1-9.
131. Wang L, McDonnell SK, Slusser JP, et al., Two common chromosome 8q24 variants are associated with increased risk for prostate cancer. Cancer Res 2007; 67: 2944-50.
132. Xu J, Mo Z, Ye D, et al., Genome-wide association study in Chinese men identifies two new prostate cancer risk loci at 9q31.2 and 19q13.4. Nat Genet 2012; 44: 1231-5.
133. Camp NJ, Farnham JM, Wong J, et al., Replication of the 10q11 and Xp11 prostate cancer risk variants: results from a Utah pedigree-based study. Cancer. Epidemiol Biomarkers Prev 2009; 18: 1290-4.
134. Pomerantz MM, Shrestha Y, Flavin RJ, et al., Analysis of the 10q11 cancer risk locus implicates MSMB and NCOA4 in human prostate tumorigenesis. PLoS Genet 2010; 6: e1001204
135. Zheng SL, Stevens VL, Wiklund F, et al., Two independent prostate cancer risk-associated Loci at 11q13. Cancer Epidemiol Biomarkers Prev 2009; 18: 1815-20.
136. Bonilla C, Hooker S, Mason T, et al., Prostate cancer susceptibility Loci identified on chromosome 12 in African Americans. PLoS ONE 2011; 6: e16044
137. Feng J, Sun J, Kim ST, et al., A genome-wide survey over the ChIP-on-chip identified androgen receptor-binding genomic regions identifies a novel prostate cancer susceptibility locus at 12q13.13. Cancer Epidemiol Biomarkers Prev 2011; 20: 2396-403.
138. Sun J, Zheng SL, Wiklund F, et al., Evidence for two independent prostate cancer risk-associated loci in the HNF1B gene at 17q12. Nat Genet 2008; 40: 1153-5.
139. Breyer JP, Avritt TG, McReynolds KM, et al., Confirmation of the HOXB13 G84E germline mutation in familial prostate cancer. Cancer Epidemiol Biomarkers Prev 2012; 21: 1348-53.
140. Ewing CM, Ray AM, Lange EM, et al., Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med 2012; 366: 141-9.
141. Parikh H, Wang Z, Pettigrew KA, et al., Fine mapping the KLK3 locus on chromosome 19q13.33 associated with prostate cancer susceptibility and PSA levels. Hum Genet 2011; 129: 675-85.
142. Berry R, Schroeder JJ, French AJ, et al., Evidence for a prostate cancer-susceptiblity locus on chromosome 20. Am J Hum Genet 2000; 67: 82-91.
143. Johanneson B, McDonnell SK, Karyadi DM, et al., Family-based association analysis of 42 hereditary prostate cancer families identifies the Apolipoprotein L3 region on chromosome 22q12 as a risk locus. Hum Mol Genet 2010; 19: 3852-62.
144. Mattila H, Schindler M, Isotalo J, et al., NMD and microRNA expression profiling of the HPCX1 locus reveal MAGEC1 as a candidate prostate cancer predisposition gene. BMC Cancer 2011; 11: 327
145. Castro E, Goh C, Leongamornlert D, et al., Effect of BRCA mutations on metastatic relapse and cause-specific survival after radical treatment for localised prostate cancer. Eur Urol 2015; 68: 186-93.
146. Schumacher FR, Berndt SI, Siddiq A, et al., Genome-wide association study identifies new prostate cancer susceptibility loci. Hum Mol Genet 2011; 20: 3867-75.